Neoleukin Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NLTX and buy or sell other stocks, ETFs, and their options commission-free!About NLTX
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
CEORachel L. McMinn, PhD
CEORachel L. McMinn, PhD
Employees107
Employees107
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees107
Employees107
NLTX Key Statistics
Market cap444.59M
Market cap444.59M
Price-Earnings ratio-4.41
Price-Earnings ratio-4.41
Dividend yield—
Dividend yield—
Average volume196.21K
Average volume196.21K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$37.27
52 Week high$37.27
52 Week low$6.88
52 Week low$6.88
Stock Snapshot
As of today, Neoleukin Therapeutics(NLTX) shares are valued at $30.09. The company's market cap stands at 444.59M, with a P/E ratio of -4.41.
On 2025-12-17, Neoleukin Therapeutics(NLTX) stock opened at —, reached a high of —, and a low of —.
The Neoleukin Therapeutics(NLTX)'s current trading volume is 0, compared to an average daily volume of 196.21K.
In the last year, Neoleukin Therapeutics(NLTX) shares hit a 52-week high of $37.27 and a 52-week low of $6.88.
In the last year, Neoleukin Therapeutics(NLTX) shares hit a 52-week high of $37.27 and a 52-week low of $6.88.
People also own
Based on the portfolios of people who own NLTX. This list is generated using Robinhood data, and it’s not a recommendation.